Analysts Set Lantheus Holdings, Inc. (NASDAQ:LNTH) PT at $126.00

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $126.00.

Several research analysts recently commented on LNTH shares. Truist Financial dropped their target price on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Leerink Partners boosted their price objective on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. B. Riley increased their target price on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. JMP Securities dropped their price target on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. Finally, Redburn Atlantic assumed coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company.

Lantheus Stock Performance

LNTH opened at $105.55 on Wednesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The company has a market cap of $7.33 billion, a PE ratio of 16.11 and a beta of 0.50. The stock has a 50-day moving average of $104.37 and a 200-day moving average of $82.38. Lantheus has a 52-week low of $50.20 and a 52-week high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company had revenue of $394.10 million for the quarter, compared to the consensus estimate of $382.12 million. During the same period in the previous year, the company earned $1.40 EPS. The firm’s revenue for the quarter was up 22.5% compared to the same quarter last year. As a group, equities research analysts forecast that Lantheus will post 5.99 earnings per share for the current fiscal year.

Insider Transactions at Lantheus

In related news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $123.15, for a total value of $41,994.15. Following the completion of the transaction, the chief accounting officer now directly owns 62,216 shares in the company, valued at $7,661,900.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the sale, the chief accounting officer now directly owns 62,216 shares in the company, valued at approximately $7,661,900.40. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, President Paul Blanchfield sold 2,000 shares of the stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the transaction, the president now directly owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. The disclosure for this sale can be found here. In the last quarter, insiders have sold 40,852 shares of company stock valued at $3,922,001. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Lantheus

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Daiwa Securities Group Inc. acquired a new position in Lantheus during the first quarter worth $1,269,000. Clearbridge Investments LLC lifted its holdings in Lantheus by 45.4% during the 4th quarter. Clearbridge Investments LLC now owns 538,782 shares of the medical equipment provider’s stock valued at $33,404,000 after purchasing an additional 168,114 shares during the last quarter. Nordea Investment Management AB boosted its position in Lantheus by 42.6% in the first quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider’s stock valued at $2,932,000 after buying an additional 14,147 shares in the last quarter. Hancock Whitney Corp boosted its position in Lantheus by 265.6% in the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock valued at $1,254,000 after buying an additional 14,639 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in Lantheus during the second quarter worth about $290,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.